Q-omics provides the consensus-scored IL17C profile across patient tissues and cancer cell-line models. IL17C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL17C is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, IL17C RNA expression shows 12,070 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where IL17C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17C survival associations across molecular data types. IL17C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17C RNA expression–survival associations across cancer types. High IL17C expression shows unfavorable associations in UVM, ACC, BLCA, KIRC, THCA and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for IL17C RNA expression.
This table summarizes IL17C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IL17C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17C shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, THCA, BRCA and ESCA. The COAD box plot shows higher IL17C RNA expression in tumor versus normal tissue (log2 FC = +0.535, t-test p < 0.001).
This table shows molecular features associated with IL17C in patient tissues and cancer cell lines. In patient samples, IL17C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
